GlassScriptPhysician profile
Frank Xing
NPI 1750792545
$22,466.88
in general payments reported to CMS, 2019-2025
54 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $369 · 2021: $4,449 · 2022: $6,012 · 2023: $4,287 · 2024: $4,257 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,413.17 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,211.29 | 2021-2025 | Botox, Duopa, Ubrelvy |
| Abbott Laboratories | $1,744.48 | 2022 | |
| Mdd US Operations, LLC | $1,428.46 | 2021-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $1,382.52 | 2019-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $1,288.62 | 2021-2025 | Nuplazid, Daybue |
| Biogen, INC. | $1,199.59 | 2020-2025 | Vumerity, Avonex, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,187.37 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,063.70 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Amneal Pharmaceuticals LLC | $923.32 | 2020-2025 | Crexont, Rytary |
| Ipsen Biopharmaceuticals, INC | $880.51 | 2021-2025 | Dysport |
| Ucb, INC. | $849.40 | 2020-2025 | Rystiggo, Nayzilam, Zilbrysq |
| Merz Pharmaceuticals, LLC | $831.37 | 2021-2025 | Xeomin, Inbrija |
| Sk Life Science, INC. | $791.13 | 2020-2025 | |
| Eisai INC. | $538.64 | 2020-2023 | |
| Kyowa Kirin, INC. | $516.21 | 2020-2024 | Nourianz |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Xing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.